Overview of Clinical Data and Treatment Selection in Later-Line HER2+ Metastatic Breast Cancer
Panelists discuss how clinical data and treatment selection in later-line HER2+ metastatic breast cancer are informed by the latest therapeutic advancements, including targeted therapies like trastuzumab deruxtecan (T-DXd) and tucatinib, to optimize patient outcomes and manage progression.
EP: 1.Overview of Clinical Data and Treatment Selection in Later-Line HER2+ Metastatic Breast Cancer
EP: 2.Managing T-DXd-Related Toxicity and Intolerance in Later-Line HER2+ Breast Cancer
EP: 3.Third-Line Approach: 54-Year-Old Patient Treated With Tucatinib-Based Regimen
EP: 4.Evolving Landscapes: Personalized Approaches in Later-Line HER2+ Treatment
EP: 5.Strategic Screening and Management of Brain Metastases in HER2+ Breast Cancer
EP: 6.Intracranial Efficacy Data with With Tucatinib and T-DXd in Brain Metastases
EP: 7.Clinical Scenario: Tucatinib-Based Regimens in the Management of Brain Metastases in the 2nd-Line Metastatic Setting
EP: 8.Evolving Frontline Treatment Strategies and Future Directions in HER2+ Breast Cancer
EP: 9.Managing Brain Metastases in Patients with HER2+ Metastatic Breast Cancer
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
